In fiscal year 2023 — Oct. 1–Sept. 30, 2023 — Oak Ridge National Laboratory was awarded more than $8 million in technology maturation funding through the Department of Energy’s Technology Commercialization Fund, or TCF.
Speakers, scientific workshops, speed networking, a student poster showcase and more energized the Annual User Meeting of the Department of Energy’s Center for Nanophase Materials Sciences, or CNMS, Aug. 7-10, near Market Square in downtown Knoxville, Tennessee.
Dean Pierce of ORNL and a research team led by ORNL’s Alex Plotkowski were honored by DOE’s Vehicle Technologies Office for development of novel high-performance alloys that can withstand extreme environments.
ORNL will team up with six of eight companies that are advancing designs and research and development for fusion power plants with the mission to achieve a pilot-scale demonstration of fusion within a decade.
Tomonori Saito, a distinguished innovator in the field of polymer science and senior R&D staff member at ORNL, was honored on May 11 in Columbus, Ohio, at Battelle’s Celebration of Solvers.
Chemist Jeff Foster is looking for ways to control sequencing in polymers that could result in designer molecules to benefit a variety of industries, including medicine and energy.
The U.S. Departments of Energy and Defense teamed up to create a series of weld filler materials that could dramatically improve high-strength steel repair in vehicles, bridges and pipelines.
Larry Allard, a distinguished research staff member at Oak Ridge National Laboratory, has been named a Fellow of the Microanalysis Society.
A team led by the U.S. Department of Energy’s Oak Ridge National Laboratory demonstrated the viability of a “quantum entanglement witness” capable of proving the presence of entanglement between magnetic particles, or spins, in a quantum material.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.